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 Abstract 
Considerable evidence indicates that adenosine A2A receptors (A2ARs) modulate cholinergic 
neurotransmission, nicotinic acetylcholine receptor (nAChR) function, and nicotine-induced 
behavioural effects.  To explore the interaction between A2A and nAChRs, we examined if the 
complete genetic deletion of adenosine A2ARs in mice induces compensatory alterations in the 
binding of different nAChR subtypes, and whether the long-term effects of nicotine on 
nAChR regulation are altered in the absence of the A2AR gene.  Quantitative autoradiography 
was used to measure cytisine-sensitive [
125
I]epibatidine and [
125
I]α-bungarotoxin binding to 
α4β2* and α7 nAChRs, respectively, in brain sections of drug-naïve (n=6) or nicotine treated 
(n=5-7), wild-type and adenosine A2AR knockout mice. Saline or nicotine (7.8 mg/kg/day; 
free-base weight) were administered to male CD1 mice via subcutaneous osmotic minipumps 
for a period of 14 days. Blood plasma levels of nicotine and cotinine were measured at the 
end of treatment.  There were no compensatory developmental alterations in nAChR subtype 
distribution or density in drug-naïve A2AR knockout mice.  In nicotine treated wild-type mice, 
both α4β2* and α7 nAChR binding sites were increased compared with saline treated 
controls. The genetic ablation of adenosine A2ARs prevented nicotine-induced upregulation of 
α7 nAChRs, without affecting α4β2* receptor upregulation.  This selective effect was 
observed at plasma levels of nicotine that were within the range reported for smokers (10-50 
ng ml
-1
). Our data highlight the involvement of adenosine A2ARs in the mechanisms of 
nicotine-induced α7 nAChR upregulation, and identify A2ARs as novel pharmacological 
targets for modulating the long-term effects of nicotine on α7 receptors.   
 
Keywords: Adenosine A2A; knockout mice; nicotine; nAChRs; upregulation; quantitative 
autoradiography 
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1. Introduction 
Neuronal nicotinic acetylcholine receptors (nAChRs) are a heterogeneous family of 
pentameric ligand-gated cation channels, classified according to subunit composition and 
pharmacology into α-bungarotoxin sensitive, homopentameric α7 receptors, and into α-
bungarotoxin insensitive, heteropentameric, non-α7 nAChRs (Albuquerque et al., 2009).  The 
latter can be assembled by combinations of different α and β nicotinic subunits, among which 
the most prevalent is the α4β2 combination (α4β2*, with the asterisk indicating the possible 
participation of additional subunits). The prolonged exposure to nicotine has been consistently 
shown to increase nAChR binding, both in cigarette smokers (Mukhin et al., 2008; Staley et 
al., 2006) and in animal models of nicotine intake (Marks et al., 1983; Schwartz and Kellar, 
1983). This neurochemical adaptation has been associated with several nicotine-induced 
behaviours, including self-administration (Metaxas et al., 2010), reward sensitisation (Hilario 
et al., 2012), locomotor activity tolerance (McCallum et al., 2006), and nicotine withdrawal 
(Gould et al., 2012). 
 
Adenosine is an ubiquitous purine neuromodulator, which exerts its effects by activating four 
types of G-protein coupled receptors, namely A1, A2A, A2B, and A3 adenosine receptors.  
Among them, adenosine A2A receptors (A2ARs) have attracted much interest as potential 
modulators of the effects of nicotine, both because of their predominant localization in brain 
circuitries that are involved in reinforcement (Ferre et al., 2007), and due to the altered 
behavioural phenotype that A2AR knockout (KO) mice exhibit in response to nicotine.  For 
instance, nicotine-induced conditioned place preference and dopamine release in the nucleus 
accumbens are attenuated in mice with genetic ablation of the adenosine A2AR gene, 
suggesting that A2ARs contribute to nicotine reward (Castane et al., 2006).  Moreover, the 
aversive response to nicotine withdrawal is blocked in A2AR KO mice, indicating that A2ARs 
*Manuscript
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modulate the motivational states associated with the cessation of chronic, but not acute, 
nicotine intake (Grieder et al., 2012).   
 
There is considerable in vitro evidence suggesting that A2ARs regulate cholinergic 
neurotransmission in the central nervous system.  Functional A2ARs are expressed on 
cholinergic nerve terminals (Preston et al., 2000; Tozzi et al., 2011), and their activation 
increases the release of acetylcholine (ACh) in the hippocampus (Rebola et al., 2002; 
Rodrigues et al., 2008) and the striatum (Gubitz et al., 1996; Kirkpatrick and Richardson, 
1993).  A2AR-mediated ACh release in the rodent striatum has also been demonstrated in vivo, 
suggesting that striatal cholinergic neurotransmission is tonically influenced by adenosine 
acting on A2ARs (Kurokawa et al., 1996).  Moreover, electrophysiological recordings from 
cell lines or neuronal cultures co-expressing A2A and nAChRs, reveal that tonic A2AR 
activation is required for sustaining the functional response of nAChRs to repeated ACh or 
nicotine exposure, indicating that A2ARs may confer a gain of function to nAChRs (Di 
Angelantonio et al., 2011). 
 
Despite the prominent role of adenosine A2ARs in regulating cholinergic neurotransmission, 
nAChR function, and nicotine-induced behaviour, the potential modulatory effects of A2ARs 
on the expression of distinct nAChR subtypes remain unknown.  Based on the evidence 
suggesting that A2AR activation tonically regulates cholinergic neurotransmission and nAChR 
function, we hypothesized that compensatory neuroadaptations might occur in the nicotinic 
cholinergic system when A2ARs are compromised.  To test this hypothesis, the distribution 
and binding densities of α4β2* and α7 nAChRs were quantified in brain sections of drug-
naïve, wild-type (WT) and homozygous (-/-) A2AR KO mice, using quantitative receptor 
autoradiography.  In addition, as A2AR activity regulates the functional and behavioural 
response to nicotine, we reasoned that adenosine A2ARs may also modulate the neuroadaptive 
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changes that occur in nAChR binding, following chronic nicotine treatment. To investigate 
the effects of A2ARs on nicotine-induced upregulation, α4β2* and α7 nAChRs binding levels 
were measured in brain sections of WT and A2AR KO mice, following 14 days of nicotine 
administration.  
 
2 Materials and methods 
2.1 Generation of the adenosine A2AR KO mouse and experimental conditions 
All animal care and experimental procedures complied with protocols approved by the UK 
Home Office, Animals (Scientific Procedures) Act, 1986.  All studies are reported in 
accordance with the ARRIVE guidelines (McGrath et al., 2010), and were designed to 
minimise suffering and to reduce the number of animals used.  CD1 adenosine A2AR KO 
mice, originally generated by Ledent et al. (1997), were obtained from the breeding colony of 
the University of Surrey, as previously detailed (Bailey et al., 2004a).  Briefly, mutant mice 
were obtained from heterozygote breeding pairs, which originated from the individual 
crossing of a number of heterozygote males from the existing colony, each with a WT female 
of the CD1 strain, which was purchased from an external supplier (Charles River, UK).  All 
mice were genotyped at weaning using a polymerase chain reaction (PCR) based method.  
Tail tip samples were collected at 3 weeks of age, and DNA was extracted using the DNeasy 
tissue kit, according to the manufacturers’ instructions (QIAGEN, Germany). 
 
Adult, 8-12 weeks old, male CD1 mice were used in all experiments (total number: 36).  The 
animals were individually housed in a temperature controlled environment, under a 12 h 
light/dark cycle (lights on: 7.00 am).  Food and water were available ad libitum.   
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2.2 Confirmation of genotype with autoradiographic binding  
To confirm the genotype of the animals used in the present studies, brain sections of WT and 
KO mice were processed for A2AR binding according to Bailey et al. (2004b).  Briefly, 
sections were pre-incubated for 30 min in 170 mM Tris-HCl buffer, containing 1 mM EDTA 
(pH 7.4, room temperature). Sections were then incubated for 2 h at room temperature, in 170 
mM Tris-HCl buffer, containing 10 nM [
3
H]CGS21680 (PerkinElmer; specific activity 30
 
Ci/mmol), 10 nM MgCl2, and 2 U/ml adenosine deaminase (pH 7.4).  Incubations were 
terminated by 3 x 5 min washes into ice cold 50 mM Tris buffer (pH 7.4), and a rapid rinse in 
ice cold water.  Radioligand bound sections were apposed for a period of 3 weeks to Kodak 
BioMax MR-1 film (Sigma-Aldrich, UK).   
 
2.3 Quantitative autoradiography of α7 and α4β2* nAChRs in drug-naïve WT and 
adenosine A2AR KO CD1 mice 
To examine whether compensatory changes occur in different subtypes of nAChR after the 
genetic deletion of adenosine A2ARs, quantitative autoradiography of α7 and α4β2* nAChRs 
was performed using brain sections from drug-naïve, WT and adenosine A2AR KO CD1 mice 
(n=6).  Animals were killed by cervical dislocation and brains were immediately removed and 
frozen in isopentane on dry ice.  The brains were stored at -80 
o
C for a maximum period of 1 
month before being processed for quantitative autoradiography of α7 and α4β2* nAChRs, as 
detailed in Metaxas et al. (2012). Tissue sectioning was carried out at -21 °C, using a Microm 
HM505E cryostat (Carl Zeiss, Germany).  Multiple, adjacent 20 µm coronal brain sections 
were collected at 300 µm intervals, from rostral to caudal levels.   
 
For heteromeric nAChRs, sections were pre-incubated for 10 min at room temperature in 
Tris-HCl buffer (pH 7.4), containing 120 mM NaCl, 5 mM KCl, 2.5 mM CaCl2, and 1 mM 
MgCl2. Sections were then incubated for 2 h at room temperature in the same buffer, 
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containing 100 pM of [
125
I]epibatidine (specific activity
 
2,200 Ci mmol
-1
, PerkinElmer).  
Determination of subtype-specific heteromeric nAChR binding was performed using adjacent 
sections
 
from each brain, in order to measure total [
125
I]epibatidine binding (no competing 
ligand), and [
125
I]epibatidine binding in the presence of 20 nM cytisine (Sigma-Aldrich, UK).  
To determine non-specific binding (NSB), further adjacent sections were incubated with 
[
125
I]epibatidine in the presence of 300 µM of (–) nicotine hydrogen tartrate salt (Sigma-
Aldrich, UK).  Competition of [
125
I]epibatidine binding by ‘cold’ cytisine has been used to 
reveal two subpopulations of nAChRs with high and low affinity for cytisine (Whiteaker et 
al., 2002).  The epibatidine binding sites with high affinity for cytisine (cytisine-sensitive 
[
125
I]epibatidine binding sites) correspond primarily to α4β2* nAChRs, and were calculated 
following the subtraction of cytisine-resistant from total [
125
I]epibatidine binding values.  
Incubations were terminated by 2 x 10 min washes into ice-cold 50 mM Tris-HCl buffer (pH 
7.4), and a rapid rinse in ice-cold water.  Radioligand bound sections were apposed to 
BioMax MR-1 film for 24 h.   
 
For homopentameric α7 nAChRs, sections were pre-incubated for 30 min at room 
temperature in assay buffer (50 mM Tris-HCl, 1% w/v BSA; pH 7.4).  Adjacent, non-specific 
binding sections were pre-incubated in the same buffer, containing 1 mM of (–) nicotine 
hydrogen tartrate. Sections were then incubated for a period of 3 h at room temperature in 
assay buffer, containing 3 nM of [
125
I]α-bungarotoxin (specific activity 250 Ci mmol
-1
, GE 
Healthcare).  Adjacent sections were incubated in the same buffer, in the presence of 1 mM (–
) nicotine hydrogen tartrate.  Specific α7 nAChR binding was calculated after the subtraction 
of NSB from total binding values.  Incubations were terminated by 3 x 10 min washes into ice 
cold 50 mM Tris buffer (pH 7.4), and a rapid rinse in ice cold water.  Sections were apposed 
to Kodak BioMax MR-1 film for a period of 7 days.  
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Quantitative analysis of receptor binding was performed by video-based computerised 
densitometry using an MCID image analyser (InterFocus Imaging, UK), as detailed 
previously (Kitchen et al., 1997).  Briefly, optical density values were quantified from 
14
C 
microscales, which had been cross-calibrated to 
125
I standards of known radioactive 
concentration (GE Healthcare, UK).  The optical density values were subsequently entered 
with their corresponding radioactivity values into a calibration table, and the relationship 
between radioactivity and optical density was determined using the MCID software.  All brain 
structures were identified by reference to the mouse atlas of Franklin and Paxinos (2001).   
 
2.4 Chronic nicotine treatment 
2.4.1 Minipump preparation and implantation 
Saline or nicotine hydrogen salt (Sigma-Aldrich, UK) were administered to WT and 
adenosine A2AR KO CD1 mice, using mini osmotic pumps (n=5-7; ALZET
®
2002 model, 
Charles River, UK).  The concentration of the nicotine salt solution was adjusted according to 
animal weight, to achieve a daily nicotine dose of 7.8 mg kg
-1
 (free-base weight), which was 
delivered for a period of 14 days, at a rate of 0.5 µl h
-1
.  This dose was chosen for its ability to 
induce upregulation of nAChR binding in the mouse brain (Davis et al., 2005; Marks et al., 
2004), and to produce blood plasma levels of nicotine comparable with the human condition 
(see results).  
 
For minipump implantation, animals were anaesthetised with an isoflurane/oxygen vapour 
mixture (3.5%-4.5%; Isoflo, Abbott Laboratories Ltd, UK), which was delivered at a flow rate 
of 450 ml min
-1
 (U400 unit, Royem Scientific, UK). Under aseptic conditions, a single 
incision was made along the midline of the back, to reveal the subcutaneous layer.  Blunt 
ended scissors were used to form a subcutaneous compartment, in which an osmotic 
minipump was placed parallel to the spine, with the flow moderator pointing away from the 
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incision, which was subsequently closed using 1-2 Michelle clips.  Mice were allowed to 
recover from the operating procedure in a heated chamber before being transferred to their 
home cage, where they remained for the duration of this study.  
 
2.4.2 Quantitative autoradiography of α7 and α4β2* nAChRs in nicotine treated WT 
and adenosine A2AR KO CD1 mice 
Saline and nicotine treated, WT and A2AR KO mice were killed by cervical dislocation on day 
14 after minipump implantation. The brains were immediately removed, rapidly frozen in 
isopentane at -20 
o
C, and processed for quantitative autoradiography of α7 and α4β2* 
nAChRs, using [
125
I]α-bungarotoxin (specific activity 152
 
Ci mmol
-1
,
 
PerkinElmer) and 
[
125
I]epibatidine (specific activity
 
2,200 Ci mmol
-1
, PerkinElmer) respectively, as detailed in 
section 2.3. 
 
2.4.3 Determination of plasma nicotine and cotinine levels 
Following cervical dislocation, ~ 800 μl of trunk blood were collected from each mouse into 
ice-cold, heparinized tubes, and plasma was immediately obtained by 20 min centrifugation at 
2,500 rpm in a refrigerated centrifuge.  Samples were subsequently frozen and transported in 
dry ice to ABS Laboratories Ltd, UK, for analysis of nicotine and cotinine levels using 
capillary column gas chromatography with nitrogen-phosphorus detection (Feyerabend and 
Russell, 1990).  The detection limit for nicotine and cotinine was 0.1 ng ml
-1
.  
 
2.5 Statistical analysis 
Two-way ANOVA for the factors genotype and region was used for the comparison of 
quantitative measures of α4β2* and α7 nAChRs in brain regions of drug naïve, WT and 
adenosine A2AR KO mice.   
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Three-way ANOVA for the factors treatment, genotype and brain region was used to compare 
receptor binding levels in saline and nicotine treated, WT and adenosine A2AR KO animals.  
Where ANOVA yielded significant main effects, Fisher’s LSD post hoc analysis was used to 
investigate differences in radioligand binding between groups in individual brain regions.  
Plasma levels of nicotine and cotinine were compared between nicotine treated WT and A2AR 
KO mice using two-tailed Student’s t-tests.  Statistical significance was set at alpha level of 
<0.05. All data were analysed using the Statistica software (Statsoft Inc., France), and are 
presented as the mean ± SEM of n animals/group. 
 
3. Results 
3.1 Confirmation of genotype 
Labeling of A2AR binding sites by [
3
H]CGS21680 was dense in the striatum of WT mice, and 
completely absent in the brains of homozygous knockout mice, confirming the genotype of 
the animals used in this study (Supplementary Figure S1). 
 
3.2 Lack of genotype effect on neuronal nAChR binding levels in naïve CD1 mice 
To investigate whether deletion of the gene encoding for the adenosine A2AR alters the 
constitutional expression of nAChRs, quantitative autoradiography of heteromeric and 
homopentameric nAChRs was carried out in brain sections of drug-naïve WT and A2AR KO 
mice.  The pattern of regional distribution of all nAChR subtypes analysed was identical 
between WT and adenosine A2AR KO mice. The majority of CD1 mouse brain 
[
125
I]epibatidine binding sites were of the cytisine-sensitive, α4β2* nAChR subtype. High 
levels of α4β2* nAChR binding were observed in thalamic regions, followed by moderate 
levels in cortical and dopaminergic regions, and low levels in the medial habenula and the 
hippocampus (Figure 1A).  Exceptionally high levels of cytisine-resistant [
125
I]epibatidine 
binding were observed in the medial habenula and the fasciculus retroflexus (Figure 1B).  
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[
125
I]α-bungarotoxin binding to α7 nAChRs was dense in nuclei of the hypothalamus, 
hippocampus, and the amygdala, but virtually absent in the thalamus (Figure 1C).  Two-way 
ANOVA for the factors genotype and brain region showed no significant genotype effect and 
no significant genotype by region interaction effects on cytisine-sensitive [genotype: 
F(1,196)=0.11, p>0.05; interaction: F(19,196)=0.67, p>0.05] or cytisine-resistant [
125
I]epibatidine 
binding levels [genotype: F(1,108)=1.83, p>0.05; interaction: F(10,108)=1.13, p>0.05].  Similarly, 
there was no effect of genotype on [
125
I]α-bungarotoxin binding levels [genotype: 
F(1,165)=0.04, p>0.05; interaction: F(18,165)=0.30, p>0.05].   
 
3.3 Plasma levels of nicotine and cotinine following chronic nicotine treatment 
14 days of nicotine administration at a daily dose of 7.8 mg kg
-1
 produced similar plasma 
levels of nicotine and cotinine in WT and adenosine A2AR KO mice. The mean plasma levels 
of nicotine were 38.1±5.1 ng ml
-1 
for WT mice and 31.2±3.2 ng ml
-1 
for A2AR KO animals 
[t(1,10)=1.8, p>0.05; Student’s t-test].  Plasma levels of cotinine were 77.7±8.5 ng ml
-1 
for WT 
and 66.3±7.9 ng ml
-1 
for KO
 
mice [t(1,10)=0.9, p>0.05].  In saline treated mice, nicotine and 
cotinine concentrations were < 1 ng ml
-1
.  
 
3.4 The genetic deletion of adenosine A2ARs prevents nicotine-induced upregulation of 
α7, but not α4β2* neuronal nAChRs  
For heteromeric nAChRs, the density of cytisine-sensitive and cytisine-resistant 
[
125
I]epibatidine binding sites is detailed for all brain areas analysed in Tables 1 and 2, 
respectively.  Administration of nicotine for 14 days resulted in a significant overall regions 
increase of α4β2* nAChR binding in the brains of nicotine treated mice compared to saline 
controls [treatment: F(1,515)=14.47, p<0.001], irrespective of genotype [genotype: F(1,515)=0.73, 
p>0.05; genotype by treatment interaction: F(1,515)=1.2, p>0.05; 3-way ANOVA].  In WT 
mice, nicotine-induced changes in binding varied from region to region, with areas of the 
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hippocampus (65.4%), cortex (43.3%) and hypothalamus (22.8%) showing the largest 
increases, and nuclei of the thalamus being resistant to nicotine-induced alterations in α4β2* 
nAChR binding (Table 1).  In both genotypes, cytisine-sensitive [
125
I]epibatidine binding sites 
were significantly elevated in the frontal association cortex, primary motor cortex, secondary 
motor cortex, visual cortex, and auditory cortex of nicotine treated animals, compared with 
their respective saline controls (LSD post hoc tests).   
 
No main effects of genotype [F(1,320)=0.17, p>0.05], treatment [F(1,320)=3.84, p>0.05] or 
interaction combination [F(1,320)=0.40, p>0.05] on cytisine-resistant [
125
I]epibatidine binding 
levels were observed following chronic nicotine administration (3-way ANOVA). 
Representative autoradiograms of heteromeric nAChR binding in brain sections of WT and 
mutant mice are shown in Figure 2.    
 
For α7 nAChRs, there were significant treatment [F(1,360)=11.82, p<0.001] and genotype by 
treatment interaction effects [F(1,360)=5.57, p<0.01] on [
125
I]α-bungarotoxin binding levels, 
with no significant overall main effects of genotype [F(1,360)=0.46, p>0.05; 3-way ANOVA].  
Thus, chronic nicotine administration increased α7 nAChR binding compared with saline, but 
this effect was modulated by the genetic deletion of adenosine A2ARs, and was not observed 
in the brains of A2AR KO animals (Table 3).  In WT mice, nicotine-induced upregulation of 
α7 nAChRs was less pronounced than that of α4β2* nAChRs, and no significant region-
specific increases in [
125
I]α-bungarotoxin binding sites were observed between nicotine and 
saline treated animals (p>0.05; LSD post hoc tests).  The mean percentage of α7 nAChR 
upregulation across all brain areas analyzed was 32.6% for WT and 6.2% for adenosine A2AR 
KO mice.  Between-group comparisons across all brain regions showed higher [
125
I]α-
bungarotoxin binding levels in nicotine treated WT animals, compared both with saline 
treated WT (p<0.001) and nicotine treated mutant mice (p<0.05; LSD post hoc tests).  
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Moreover, no difference in α7 nAChR binding sites was observed between nicotine and saline 
treated A2AR KO animals (p>0.05), or between saline treated control and mutant mice 
(p>0.05; LSD post hoc tests). Representative autoradiograms of α7 nAChR binding are shown 
in Figure 3.  
 
4. Discussion 
The current study highlights a novel role for A2ARs in modulating the long term effects of 
nicotine treatment on α7 nAChRs. We show that the genetic deletion of adenosine A2ARs 
prevents nicotine-induced upregulation of α7, but not α4β2* nAChRs, indicating that A2ARs 
regulate the nicotinic cholinergic response to chronic nicotine administration via an α7 
receptor-specific mechanism. 
  
In control CD1 mice, 14 days of nicotine administration via osmotic minipumps increased 
cytisine-sensitive [
125
I]epibatidine and [
125
I]α-bungarotoxin binding to α4β2* and α7 nAChRs, 
respectively. The pattern and extent of nicotine-induced upregulation differed between the 
two receptor subtypes, with α4β2* nAChR upregulation showing marked regional variability 
and being more pronounced than that of α7 nAChRs.  These observations are in complete 
agreement with a substantial number of reports, which have established that nAChR 
upregulation is a time and dose dependent phenomenon, varying quantitatively and 
qualitatively according to nAChR subunit composition (Marks et al., 1985; Marks et al., 1986; 
Pauly et al., 1989; Sanderson et al., 1993), and cell-specific neuronal distribution (Nashmi et 
al., 2007).  Thus, α4β2* nAChRs, which have high affinity for nicotine, are more readily 
upregulated compared with low-affinity α7 nAChRs, a differential regulation that occurs in 
mice (Sparks and Pauly, 1999), rats (Mugnaini et al., 2002) and humans (Teaktong et al., 
2004).  For α7 nAChRs, in particular, we observed a 30% overall increase in [
125
I]α-
bungarotoxin binding sites in nicotine treated WT mice, which is consistent with the 
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magnitude of nicotine-induced upregulation previously reported for the α7 receptor subtype 
by in vitro (Barrantes et al., 1995; Peng et al., 1997; Ridley et al., 2001) and in vivo studies 
(Pauly et al., 1991; Rasmussen and Perry, 2006).  These results render the dose of chronic 
nicotine used appropriate for investigating the effects of adenosine A2AR deletion on nicotine-
induced upregulation, and confirm that the overall effects of nicotine on the binding of 
distinct nAChR subtypes are conserved, not only among inbred (Marks et al., 1991), but also 
in outbred strains of animals.  In addition, increased nAChR binding was measured at plasma 
levels of nicotine that are within the range reported for smokers (10-50 ng ml
-1
; Benowitz and 
Jacob, 1984; Russell et al., 1980), and similar to those achieved in mice after long-term 
treatment with comparable doses of nicotine, administered either via osmotic minipumps 
(Metzger et al., 2007), constant i.v. infusion (Marks et al., 2004), or in the drinking water 
(Pekonen et al., 1993).  The current experimental design thus resulted in blood plasma levels 
of nicotine that are physiologically relevant to the human condition.   
 
Unlike α4β2* nAChR binding, which was increased both in nicotine treated WT and 
adenosine A2AR KO mice, the upregulation of α7 nAChRs by chronic nicotine was abolished 
in  A2AR KO animals.  This effect is unlikely to be caused by genotype-induced differences in 
the availability of nicotine to the systemic circulation, as plasma nicotine and cotinine 
concentrations were similar in WT and KO mice, indicating that the deletion of A2ARs does 
not affect nicotine metabolism. Moreover, the specific effects of A2AR deletion on the 
upregulation of α7 nAChRs cannot be related to developmental compensatory alterations in 
nAChR binding levels, as the distribution and densities of both α7 and α4β2* nAChRs were 
identical in drug-naïve or untreated control and mutant mice.  These observations suggest that 
the effects of A2ARs on α7 receptor regulation are not exerted tonically, but require activation 
of the nicotinic cholinergic system by nicotine.  Our results thus point towards the existence 
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of specific, nicotine-induced interactions of adenosine A2ARs with α7, but not α4β2* 
nAChRs.  
 Although the upregulation of nAChR binding constitutes a profound and well-documented 
neurochemical adaptation to prolonged nicotine exposure, the exact mechanisms underlying 
the phenomenon are still the subject of intense investigation. It is becoming increasingly 
accepted, however, that distinct molecular mechanisms underpin the regulation of α4β2* vs. 
α7 nAChRs by chronic nicotine.  Thus, while changes in conformation, stoichiometry, or β2 
nicotinic subunit chaperoning have been implicated in the upregulation of α4β2* nAChRs 
(Govind et al., 2009; Govind et al., 2012; Lester et al., 2009), similar nicotine-induced 
alterations do not mediate the upregulation of homopentameric α7 nAChRs. Instead, increases 
in α7, but not α4β2* nAChRs, have been shown to require protein synthesis and glycosylation 
in cultured cortical neurons (Kawai and Berg, 2001), further suggesting that different 
molecular mechanisms may underlie the upregulation of distinct nAChR subtypes.  In this 
context, the present study clearly demonstrates that A2ARs are specifically involved in the 
mechanism of nicotine-induced α7, but not α4β2* receptor upregulation.   
 
The reason for this discrepancy is unclear, but it is highly likely to involve alterations 
downstream of the adenosine A2AR. One such mechanism involves the brain-derived 
neurotrophic factor (BDNF).  The link between A2ARs and BDNF is well-documented, with 
evidence showing that A2AR activation is necessary both for regulating the expression and 
release of BDNF in the brain, and mediating BDNF’s effects on synaptic plasticity (reviewed 
in Sebastiao and Ribeiro, 2009).  In neurons cultured from the hippocampus and the ciliary 
ganglion, BDNF is known to upregulate the intracellular and surface pools of α7, but not β2* 
nAChRs (Massey et al., 2006; Zhou et al., 2004).  In addition, the interplay of A2ARs with 
BDNF and α7 nAChRs is evidenced in the fact that adenosine deaminase or A2AR antagonists 
abolish the effects of BDNF on α7 nAChR function (Fernandes et al., 2008).  Taken together, 
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these studies suggest that mice lacking adenosine A2ARs may have deficits in BDNF-
dependent mechanisms that are specifically involved in nicotine-induced α7 nAChR 
upregulation. Interestingly, chronic nicotine treatment has been shown to elevate the 
expression or the levels of BDNF in the cortex, hippocampus and the amygdala (Aydin et al., 
2012; Czubak et al., 2009; Kenny et al., 2000).  We observed that in the above brain regions 
nicotine-induced α7 nAChR upregulation was more pronounced in WT vs. A2AR KO mice, 
whereas in the ventral tegmental area, where chronic nicotine administration does not affect 
BDNF levels (Kivinummi et al., 2011), the effects of A2AR deletion were less evident, thus 
providing further support to our suggestion.   
 
Although the involvement of adenosine A2ARs in nicotine reinforcement (Castane et al., 
2006) and withdrawal (Grieder et al., 2012) has been illustrated using mice with complete and 
permanent inactivation of the A2AR gene, little is currently known about the contribution of 
α7 nAChR upregulation to nicotine’s long-term behavioural effects. Neuroplastic alterations 
involving α7 and not β2* nAChRs, have been shown to mediate the effects of prolonged 
nicotine exposure on novelty-seeking behaviour (Besson et al., 2007). In addition, α7 nAChRs 
play a pivotal role in sustaining nicotine’s persistent effect on dopamine neuron excitability 
and, consequently, on nicotine reinforcement (Mansvelder et al., 2002; Mansvelder and 
McGehee, 2000). Moreover, the manifestation of the somatic symptoms of nicotine 
withdrawal requires the expression of α7, but not β2* nAChRs (Besson et al., 2006; Salas et 
al., 2007).  As a result, the discovery that A2ARs modulate the response of α7 nAChRs to 
chronic nicotine is likely to have important implications for intervening in nicotine-induced 
behaviours that involve this receptor subtype, including reinforcement and dependence.  In 
addition to nicotine-induced behaviour, α7 nAChRs have been aetiologically implicated in 
human neuropathology, most notably in schizophrenia (Olincy and Freedman, 2012). 
Considerable evidence indicates that the high prevalence of smoking in schizophrenics can be 
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partly attributed to the cognitive enhancing properties of nicotine, and thus to nicotine’s 
efficacy in alleviating the cognitive symptoms of schizophrenia (Ochoa and Lasalde-
Dominicci, 2007).  Nicotine’s effects on cognition are known to be mediated via α7 nAChRs 
(Mansvelder et al., 2009).  Moreover, smoking has been shown to restore α7 receptor 
expression in the hippocampus of schizophrenic patients to control levels (Mexal et al., 2010), 
suggesting a prominent role for α7 nAChR upregulation in the procognitive effect of nicotine.  
Indeed, the beneficial effects of various α7 agonists on cognition have been closely associated 
with their ability to induce α7 nAChR upregulation (Christensen et al., 2010).  It is thus 
intriguing to postulate that a pharmacotherapeutic approach which would enhance α7 nAChR 
upregulation, such as A2AR agonism, might further improve the effectiveness of α7 agonists 
in controlling the cognitive deficits in schizophrenia. In support of this suggestion, 
independent clinical and preclinical studies reveal that both dysfunction of the α7 nAChR 
(AhnAllen, 2012), and a reduced adenosinergic tone at A2ARs (Boison et al., 2012) contribute 
to the cognitive symptoms of the disorder.  
 
In conclusion, we have shown that the genetic deletion of adenosine A2ARs prevents nicotine-
induced upregulation of α7, but not α4β2* nAChRs. This modulatory effect is specific to α7 
nAChRs, it occurs at plasma levels of nicotine that are relevant to the human condition, and it 
is not due to compensatory developmental alterations in nAChR binding levels. These 
findings highlight the role of A2ARs in regulating the long term effects of nicotine treatment 
on α7 nAChRs in vivo, and suggest that A2ARs may comprise targets for novel 
pharmacological interventions, aimed at modulating the effects of chronic nicotine on α7 
nAChRs.   
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Legends to Figures 
Figure 1 Quantitative autoradiography of heteromeric and homomeric nAChRs in drug-
naïve, wild-type and adenosine A2A receptor knockout mice 
Compensatory alterations in nAChR binding levels following the genetic deletion of 
adenosine A2A receptors (A2ARs) were examined using male, drug-naive, wild-type (WT) and 
A2AR knockout (KO) CD1 mice. No genotype-induced alterations in heteromeric, cytisine-
sensitive (A) or cytisine-resistant (B) [
125
I]epibatidine binding levels were observed.  
Similarly, there was no effect of genotype on homopentameric, α7 nAChR binding levels.  
Values represent the mean±SEM of 6 animals/group. Abbreviations: FrA: Frontal Association 
Cortex, M1: Primary Motor Cortex; MS: Medial Septum; Cg: Cingulate Cortex; CPu: 
Caudate Putamen; AcbC: Nucleus Accumbens, Core; AcbSh: Nucleus Accumbens, Shell; Tu: 
Olfactory Tubercle; AV: Anteroventral Thalamic Nucleus; LPMR: Lateral Posterior Thalamic 
Nucleus; Po: Posterior Thalamic Nuclear Group; DLG: Dorsal Lateral Geniculate Nucleus; 
VLG: Ventral Lateral Geniculate Nucleus; SuG: Superficial Gray Layer of the Superior 
Colliculus; SNc: Substantia Nigra, pars Compacta; VTA: Ventral Tegmental Area; MG: 
Medial Geniculate Nucleus; MHb: Medial Habenula; fr: Fasciculus Retroflexus; CA1: 
Hippocampus, CA1 field; DEn: Dorsal Endopiriform Nucleus; Cl: Claustrum; CA3: 
Hippocampus, CA3 field; DG: Dentate Gyrus; BLA: Basolateral Amygdaloid Nucleus; PLCo: 
Posteromedial Cortical Amygdaloid Nucleus; MAN: Medial Amygdaloid Nucleus; DM: 
Dorsomedial Hypothalamic Nucleus; VM Ventromedial Hypothalamic Nucleus; LH: Lateral 
Hypothalamus; ZI: Zona Incerta; SN: Substantia Nigra. 
 
Figure 2 Representative autoradiograms of [
125
I]epibatidine binding in saline and 
nicotine treated, wild-type and adenosine A2A receptor knockout mice  
Nicotine was delivered to male CD1 mice at a daily dose of 7.8 mg kg
-1
, for a period of 14 
days. On day 14 animals were killed by cervical dislocation, and their brains were 
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immediately removed and processed for quantitative receptor autoradiography.  The panels 
show adjacent, 20 μm-thick coronal brain sections, cut at the level of the caudate putamen 
(Bregma 0.74 mm).  Sections were labeled for 2 h using 100 pM [
125
I]epibatidine, alone or in 
the presence of 20 nM cytisine. Cytisine-sensitive, α4β2* nAChR binding was calculated 
following the subtraction of cytisine-resistant from total [
125
I]epibatidine binding values. Non-
specific binding (NSB) was indistinguishable from film background.  Sections were apposed 
to Kodak BioMax MR-1 film for 24 h. The degree of nicotine-induced α4β2* nAChR 
upregulation was identical in wild-type (WT) and adenosine A2AR knockout (KO) mice.  
 
Figure 3 Representative autoradiograms of [
125
I]α-bungarotoxin binding in saline and 
nicotine treated, wild-type (WT) and adenosine A2A receptor knockout (KO) mice 
To label α7 nAChRs, adjacent brain sections from saline or nicotine-treated mice were 
incubated for 3 h with 3 nM [
125
I]α-bungarotoxin, alone or in the presence of 1mM of nicotine 
salt to calculate non-specific binding (NSB).  Sections were apposed to Kodak BioMax MR-1 
film for a period of 7 days.  The genetic ablation of adenosine A2ARs prevented nicotine-
induced α7 nAChR upregulation. 
 
 
Table 1 Quantitative autoradiography of α4β2* nAChRs in WT and adenosine 
A2AR KO mice, following chronic nicotine administration.  
Values represent the mean±SEM of 5-7 animals/group. *p<0.05, **p<0.01 vs. WT 
saline; 
#
p<0.05, 
##
p<0.01 vs. KO saline, LSD post-hoc tests.  
 
WT Nicotine vs. 
WT Saline
KO Nicotine vs. 
KO Saline
Frontal association cortex 9.6 ± 0.8 16.8 ± 1.2** 11.4 ± 0.9 14.2 ± 1.3# 75.2 25.2
Prelimbic cortex 8.8 ± 0.5 13.8 ± 0.9* 10.7 ± 1.0 13.0 ± 2.3 57.0 21.8
Cingulate cortex 11.7 ± 1.1 15.2 ± 1.6 12.8 ± 1.1 15.0 ± 2.2 29.3 17.2
Primary motor cortex 10.6 ± 0.8 14.6 ± 1.6* 10.8 ± 0.9 14.1 ± 1.9# 37.7 30.7
Secondary motor cortex 10.3 ± 0.7 14.5 ± 1.2* 10.9 ± 0.8 14.0 ± 2.1# 40.5 28.5
Visual cortex 11.6 ± 0.5 16.4 ± 0.8* 11.7 ± 1.2 16.5 ± 1.5## 41.2 40.9
10.4 ± 0.6 12.8 ± 1.3 9.7 ± 0.8 12.5 ± 1.8 23.3 29.5
Subiculum 15.1 ± 1.3 15.2 ± 1.5 15.3 ± 1.5 16.1 ± 1.4 0.5 5.2
Auditory cortex 9.3 ± 0.8 13.2 ± 1.1* 9.3 ± 0.7 13.4 ± 1.0# 42.0 44.3
Hippocampus 3.4 ± 0.3 5.7 ± 0.5 3.6 ± 0.2 5.7 ± 0.7 65.4 60.3
Hypothalamus 10.6 ± 1.1 13.0 ± 1.2 10.4 ± 0.7 13.3 ± 1.2 22.8 28.2
Nucleus accumbens
Core 10.6 ± 0.5 11.5 ± 1.8 11.2 ± 0.9 12.3 ± 1.9 8.7 10.2
Shell 10.5 ± 0.6 12.8 ± 1.6 11.3 ± 0.9 13.3 ± 2.2 21.8 17.4
Caudate putamen 13.4 ± 0.9 15.3 ± 1.9 13.6 ± 1.1 15.0 ± 2.2 14.2 11.0
Olfactory tubercle 11.7 ± 0.7 13.7 ± 1.6 12.1 ± 0.4 13.7 ± 2.0 17.3 13.6
29.9 ± 2.6 31.3 ± 3.0 31.1 ± 3.0 27.6 ± 3.0 4.7 -11.4
7.3 ± 1.1 5.7 ± 1.9 7.4 ± 0.6 7.8 ± 2.3 -21,9 5.4
Fasciculus retroflexus 7.8 ± 1.7 9.3 ± 1.9 8.5 ± 1.4 8.4 ± 1.8 19.2 -1.2
26.2 ± 2.9 24.2 ± 3.3 28.1 ± 2.6 23.8 ± 2.2 -7,6 -15.1
25.2 ± 2.3 25.0 ± 2.5 23.6 ± 2.7 23.1 ± 2.0 -0.8 -2.2
25.6 ± 3.4 24.4 ± 3.1 25.4 ± 3.2 25.5 ± 2.6 -4.8 0.2
22.0 ± 2.3 22.7 ± 3.6 22.5 ± 2.7 22.2 ± 1.9 2.9 -1.5
Medial geniculate nucleus 22.5 ± 2.5 23.1 ± 1.3 25.0 ± 1.2 24.9 ± 2.2 2.4 -0.5
17.5 ± 1.6 18.4 ± 2.5 24.5 ± 2.0 21.8 ± 0.9 5.0 -11.1
Ventral tegmental area 22.5 ± 2.5 21.6 ± 1.2 20.8 ± 1.6 21.2 ± 1.8 -3.9 2.0
23.1 ± 2.5 22.3 ± 1.2 22.9 ± 1.8 22.6 ± 2.4 -3.6 -1.2
Primary somatosensory cortex
Anteroventral thalamic nucleus
Lateral posterior thalamic nucleus
Posterior thalamic nuclear group
Medial habenula
Dorsal lateral geniculate nucleus
Ventral lateral geniculate nucleus
Superficial gray layer of the 
superior colliculus
Substantia nigra, pars compacta
Brain Region
Cytisine-sensitive [
125
I]epibatidine binding 
% change in binding
(fmol/mg tissue equivalent)
WT Saline WT Nicotine KO Saline KO Nicotine
Table(s)
Table 2 Quantitative autoradiography of cytisine-resistant [
125
I]epibatidine 
binding in WT and adenosine A2AR KO mice, following chronic nicotine 
administration. Values represent the mean±SEM of 5-7 animals/group. 
 
Subiculum 2.0 ± 0.2 2.0 ± 0.2 2.0 ± 0.2 2.3 ± 0.1
Nucleus accumbens
Core 2.9 ± 0.1 2.2 ± 0.4 2.5 ± 0.1 2.5 ± 0.1
Shell 2.7 ± 0.2 2.2 ± 0.3 2.5 ± 0.1 2.4 ± 0.1
Caudate putamen 2.5 ± 0.1 2.3 ± 0.2 2.4 ± 0.1 2.4 ± 0.1
Olfactory tubercle 1.4 ± 0.4 1.9 ± 0.2 2.0 ± 0.2 1.7 ± 0.2
Anteroventral thalamic nucleus 4.7 ± 0.2 4.8 ± 0.5 5.0 ± 0.1 4.8 ± 0.3
Lateral posterior thalamic nucleus 3.9 ± 0.2 4.2 ± 0.2 3.8 ± 0.2 4.6 ± 0.2
Posterior thalamic nuclear group 2.9 ± 0.3 3.3 ± 0.2 2.6 ± 0.3 3.2 ± 0.2
Dorsal lateral geniculate nucleus 12.9 ± 0.5 12.2 ± 1.1 12.9 ± 1.0 11.9 ± 0.9
Ventral lateral geniculate nucleus 16.9 ± 1.2 13.8 ± 1.4 15.1 ± 1.7 12.9 ± 1.4
Medial geniculate nucleus 2.7 ± 0.1 3.3 ± 0.1 2.4 ± 0.2 3.6 ± 0.3
46.8 ± 3.9 42.2 ± 3.9 48.6 ± 3.1 43.5 ± 2.9
Fasciculus retroflexus 42.4 ± 3.3 38.3 ± 2.3 41.1 ± 2.3 37.0 ± 2.4
17.3 ± 2.3 16.6 ± 2.8 15.6 ± 1.6 15.5 ± 2.4
Ventral tegmental area 5.7 ± 0.6 6.1 ± 0.5 6.9 ± 1.7 6.5 ± 0.6
Substantia nigra, pars compacta 4.7 ± 0.6 4.8 ± 0.4 3.3 ± 0.5 5.1 ± 0.5
Superficial gray layer of the superior 
colliculus
Brain Region
Cytisine-resistant [
125
I]epibatidine binding                     
(fmol/mg tissue equivalent)
WT Saline WT Nicotine KO Saline KO Nicotine
Medial habenula
Table(s)
Table 3 Quantitative autoradiography of α7 nAChRs in WT and adenosine A2AR KO 
mice, following chronic nicotine administration. Values represent the mean±SEM of 5-7 
animals/group. 
 
WT Nicotine vs. 
WT Saline
KO Nicotine vs. 
KO Saline
Frontal association cortex 12.5 ± 2.7 18.7 ± 3.9 17.8 ± 3.3 17.0 ± 3.6 50.3 -4.4
Cingulate cortex 9.5 ± 2.8 15.3 ± 3.1 12.5 ± 0.8 10.8 ± 4.3 61.0 -13.8
Caudate putamen 16.6 ± 3.8 18.9 ± 5.0 14.7 ± 0.8 12.8 ± 2.8 13.3 -13.3
21.5 ± 3.7 27.7 ± 6.5 21.1 ± 0.7 21.8 ± 3.5 28.6 3.3
Primary motor cortex 15.2 ± 3.8 20.4 ± 5.7 15.4 ± 1.8 16.7 ± 3.8 34.1 8.5
Claustrum 21.9 ± 3.7 29.5 ± 7.3 22.1 ± 1.6 18.7 ± 3.3 34.4 -15.6
7.6 ± 2.2 13.5 ± 2.9 8.8 ± 1.9 9.9 ± 2.3 76.7 12.0
Hippocampus, CA1 16.5 ± 4.0 23.3 ± 4.4 18.4 ± 4.6 21.5 ± 4.0 41.1 17.0
Hippocampus, CA3 20.6 ± 3.5 28.6 ± 5.5 23.6 ± 4.5 26.9 ± 4.5 38.6 14.1
Dentate gyrus 12.6 ± 2.8 19.0 ± 3.2 14.3 ± 3.1 17.0 ± 2.9 50.4 18.4
14.5 ± 2.9 17.3 ± 3.1 16.8 ± 2.1 19.9 ± 3.5 19.3 18.3
15.8 ± 2.1 23.3 ± 4.5 19.6 ± 3.5 17.4 ± 2.3 47.5 -11.1
Medial amygdaloid nucleus 46.1 ± 8.0 48.2 ± 6.8 43.2 ± 2.4 47.6 ± 6.6 4.6 10.4
17.3 ± 2.7 20.4 ± 2.1 23.2 ± 3.1 23.5 ± 4.5 18.1 1.0
19.4 ± 2.1 24.4 ± 4.7 26.5 ± 6.8 25.6 ± 2.8 25.6 -3.4
Lateral hypothalamus 8.7 ± 1.4 11.1 ± 1.2 11.4 ± 1.4 12.0 ± 1.6 26.9 5.3
Zona incerta 52.0 ± 5.5 61.6 ± 8.7 50.5 ± 3.5 53.4 ± 6.4 18.4 5.8
Ventral tegmental area 26.6 ± 2.1 30.5 ± 5.0 25.8 ± 5.1 29.4 ± 2.7 14.3 13.7
Substantia nigra 7.0 ± 1.0 8.1 ± 1.0 5.7 ± 1.0 8.6 ± 1.6 16.3 51.2
32.6 6.2
Brain Region
[
125
I]α-bungarotoxin binding                            
(fmol/mg tissue equivalent)
% change in binding
WT Saline WT Nicotine KO Saline KO Nicotine
Endopiriform nucleus, dorsal 
Basolateral amygdaloid 
nucleus
Posterior thalamic nuclear 
group
Posteromedial cortical 
amygdaloid nucleus
mean increase (%)
Dorsomedial hypothalamic 
nucleus
Ventromedial hypothalamic 
nucleus
Table(s)
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